How Do Companies Avert Further Frustration among Neurologists Due to Relyvrio’s (Amylyx) Phase 3 Failure and Donanemab’s (Lilly) ...
EXTON, PA, March 12, 2024 (GLOBE NEWSWIRE) -- For neurologists tasked with delivering the distressing diagnosis of Amyotrophic Lateral Sclerosis (ALS) or Alzheimer’s Disease (AD), the upcoming months may prove equally heart-wrenching. They face the …